PRP for Knee Osteoarthritis: A 2026 Clinical Update

Knee osteoarthritis affects an estimated 250 million people globally, and in Pakistan it remains one of the leading causes of chronic pain and disability — particularly among patients over 50. For years, the management pathway was straightforward: painkillers, physiotherapy, steroid injections, and eventually joint replacement. Platelet-Rich Plasma (PRP) therapy is challenging this old paradigm, with a growing body of evidence supporting its role in slowing cartilage degeneration and providing meaningful, lasting pain relief.

What is PRP and How Does It Work in the Knee?

PRP is derived from a patient's own blood. A small volume (typically 20–40ml) is drawn, then processed through a centrifuge that concentrates the platelet fraction — normally present at 150,000–400,000 per microlitre — to 5–10 times that concentration.

Platelets contain over 30 identified growth factors, including:

• PDGF (Platelet-Derived Growth Factor) — stimulates cell proliferation and tissue repair
• TGF-β (Transforming Growth Factor-beta) — modulates inflammation and promotes matrix synthesis
• IGF-1 (Insulin-like Growth Factor) — protects chondrocytes from apoptosis
• VEGF (Vascular Endothelial Growth Factor) — promotes new blood vessel formation in synovial tissue

When injected under ultrasound guidance into the knee joint, PRP creates a concentrated regenerative environment directly at the site of degeneration. The growth factors modulate the inflammatory cytokines that drive cartilage destruction, while simultaneously stimulating the synovial cells to produce more hyaluronic acid — the joint's natural lubricant.

What Does the 2026 Evidence Say?

The evidence base for PRP in knee OA has matured considerably. A 2025 meta-analysis in the Journal of Orthopaedic Research pooling data from 34 randomised controlled trials and over 3,200 patients found that PRP significantly outperformed both hyaluronic acid injections and saline placebo for pain reduction and functional improvement at 6 and 12 months.

Key findings from recent literature:

• PRP reduces WOMAC pain scores by an average of 42% at 6 months versus 18% for HA injections
• Leukocyte-poor (LP-PRP) preparations appear superior to leukocyte-rich formulations for intra-articular use
• MRI studies show measurable cartilage volume preservation at 12 months in PRP-treated knees versus accelerated thinning in controls
• Patients with mild to moderate OA (Kellgren-Lawrence Grade 1–3) show the most robust response

Who is a Good Candidate?

PRP works best for patients with:

• Knee OA Grade 1–3 on X-ray (mild to moderate)
• Age 35–70 (younger patients may respond better due to higher growth factor release capacity)
• BMI below 35 (obesity reduces efficacy due to systemic inflammation)
• No active infection or coagulation disorder
• Not currently on anticoagulant therapy (warfarin, clopidogrel)

Patients with severe OA (Grade 4 — bone on bone) are less likely to achieve significant benefit and may be better served by joint replacement discussion. We are always transparent about this during consultation.

Our Protocol at Zainee's Aesthetics

We use an ultrasound-guided injection technique for all knee PRP procedures. This is critical — non-guided injections miss the joint space in up to 30% of cases, significantly reducing efficacy.

Our standard protocol for knee OA involves:

1. Initial assessment including X-rays and clinical examination
2. Three injections spaced 4 weeks apart (induction series)
3. Physiotherapy commenced simultaneously to optimise joint mechanics
4. Review at 3 months; maintenance injection at 6–12 months as needed

What Can You Expect After Injection?

The first 48–72 hours may involve increased joint discomfort — this is a normal inflammatory response as the platelets activate. After this settles, patients typically notice:

• Weeks 2–4: Gradual reduction in resting pain
• Months 1–3: Improved walking distance and stair tolerance
• Months 3–6: Peak functional improvement; many patients resume activities they had abandoned